Cefonicid
Cefamandole
Cholera Vaccines
Cholera
Vaccines
Vaccines, Inactivated
Cholera Toxin
An ENTEROTOXIN from VIBRIO CHOLERAE. It consists of two major protomers, the heavy (H) or A subunit and the B protomer which consists of 5 light (L) or B subunits. The catalytic A subunit is proteolytically cleaved into fragments A1 and A2. The A1 fragment is a MONO(ADP-RIBOSE) TRANSFERASE. The B protomer binds cholera toxin to intestinal epithelial cells, and facilitates the uptake of the A1 fragment. The A1 catalyzed transfer of ADP-RIBOSE to the alpha subunits of heterotrimeric G PROTEINS activates the production of CYCLIC AMP. Increased levels of cyclic AMP are thought to modulate release of fluid and electrolytes from intestinal crypt cells.
Trypanosoma cruzi
Trypanocidal Agents
Chagas Disease
Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.
United States Food and Drug Administration
Drug Approval
Immediate Dental Implant Loading
Endosseous dental implantation where implants are fitted with an abutment or where an implant with a transmucosal coronal portion is used immediately (within 1 week) after the initial extraction. Conventionally, the implantation is performed in two stages with more than two months in between the stages.
Ion Exchange Resins
Cation Exchange Resins
Anion Exchange Resins
Resins, Plant
Flammable, amorphous, vegetable products of secretion or disintegration, usually formed in special cavities of plants. They are generally insoluble in water and soluble in alcohol, carbon tetrachloride, ether, or volatile oils. They are fusible and have a conchoidal fracture. They are the oxidation or polymerization products of the terpenes, and are mixtures of aromatic acids and esters. Most are soft and sticky, but harden after exposure to cold. (From Grant & Hackh's Chemical Dictionary, 5th ed & Dorland, 28th ed)
Resins, Synthetic
Development of revised quality control limits for disk diffusion susceptibility tests of selected cephem antibiotics with Haemophilus influenzae and description of a new control strain. (1/37)
Inconsistent quality control results in disk diffusion testing of cefaclor, cefamandole, cefonicid, and cefuroxime with Haemophilus influenzae ATCC 49247 and Haemophilus test medium (HTM) prompted a search for an alternative control strain that would provide more reliable results. A five-laboratory study was conducted to evaluate two candidate H. influenzae strains as possible alternatives to the aforementioned strain. Repetitive testing of the candidate strains and H. influenzae ATCC 49247 over several days with a total of six different lots of HTM documented consistent performance of the two candidate strains and confirmed inconsistent results for some of the antibiotics with H. influenzae ATCC 49247. In particular, certain lots of HTM failed to yield cefaclor and cefamandole zone sizes within the quality control range advocated by the National Committee for Clinical Laboratory Standards. Because of the greater consistency offered by the new strains, one was selected (now designated H. influenzae ATCC 49766) to be recommended for routine quality control testing of cefaclor, cefamandole, cefonicid, cefuroxime, and the related carbacephem loracarbef. The new control strain and zone size ranges proposed here have been approved by the National Committee for Clinical Laboratory Standards in place of the previously recommended strain and zone size limits for testing of these five cephem antibiotics. (+info)Influence of angiotensin II-induced alterations in renal flow on excretion of cefonicid in isolated perfused rat kidneys. (2/37)
The effects of variations in renal perfusate flow on the excretion of cefonicid was examined in isolated perfused rat kidneys. Cefonicid, an expanded-spectrum cephalosporin, is primarily eliminated by active tubular secretion and is neither metabolized nor reabsorbed in the isolated kidney. We used angiotensin II (AII), a strong vasoconstrictor hormone of the afferent and the efferent arterioles in the kidney, to determine whether the renal and secretion clearances, as well as the excretion ratio (ER = CLR/[fu x GFR], where CLR is renal clearance, fu is the unbound fraction, and GFR is glomerular filtration rate), of this low-extraction compound can be altered by a decreased perfusion flow. Control studies were performed in the absence (n = 5) and presence (n = 4) of AII; cefonicid studies were performed in the absence (n = 4) and presence (n = 5) of AII. AII (1 to 4 ng/min) and cefonicid (5 to 10 micrograms/min) were infused into the perfusate. Cefonicid was assayed by high-performance liquid chromatography, and its protein binding was determined by ultrafiltration. AII decreased the perfusate flow rate and increased the renal vascular resistance and filtration fraction of the isolated kidney in the presence and absence of cefonicid. The glomerular filtration rate remained unchanged among the groups. The fractional excretion of glucose was low and steady, indicating a well-preserved tubular function. Although the unbound fraction was unchanged between treatments, the renal and secretion clearances and the excretion ratio of cefonicid were reduced by about 40% in the presence of AII (excretion ratios, 10.3 without AII versus 6.03 with AII). These results suggest that the altered clearance parameters of cefonicid are the result of a flow-induced change in the intrinsic secretory transport of the drug. (+info)Influence of the unbound concentration of cefonicid on its renal elimination in isolated perfused rat kidneys. (3/37)
The effect of variations in plasma protein binding on the renal excretion of cefonicid was assessed by using isolated perfused rat kidneys. Cefonicid exhibits preferential binding ex vivo to human serum albumin (HSA), as opposed to bovine serum albumin (BSA), and is eliminated mainly by tubular secretion, a process that was reported to be dependent on the total drug concentration. This contradicts previous studies with antimicrobial compounds and other drugs of low renal extraction in which the unbound drug concentration was shown to be the driving force for carrier-mediated tubular transport. To clarify this discrepancy, we performed perfusion studies by using 6% BSA at initial concentrations of 200 micrograms/ml (n = 6) and 20 micrograms/ml (n = 9) and in a combination of 4% BSA plus 2% HSA at initial concentrations of 200 micrograms/ml (n = 4). The excretion ratio [ER = CLR/(fu x GFR)] of cefonicid decreased with increasing unbound concentrations, whereas no apparent relationship with the total concentration was evident. At similar total concentrations of cefonicid, the renal clearance remained unchanged; the secretion clearance increased significantly in the 4% BSA-2% HSA experiments, reflecting the reduced unbound fraction and unbound drug concentration of cefonicid. The excretion ratio data were compatible with a model in which Michaelis-Menten kinetics were required to describe active transport and secretion was dependent on the unbound cefonicid concentration. As a result, changes in plasma protein binding as a result of drug interactions or disease states could significantly influence the tubular transport capability of compounds with low renal extraction. (+info)Cefonicid versus clindamycin prophylaxis for head and neck surgery in a randomized, double-blind trial, with pharmacokinetic implications. (4/37)
Perioperative single-dose antibiotic prophylaxis of cefonicid was compared with clindamycin in a prospective, randomized, double-blind trial of patients undergoing oncologic head and neck surgery. Antibiotics were administered intravenously beginning 1 to 2 h preoperatively. Cefonicid, 1 g, was given as a single dose. Clindamycin, 600 mg, was administered every 8 h for a total of four doses. Blood and wound drainage samples were collected for 24 h following the dose of cefonicid and assayed for total and free cefonicid concentrations, using reverse-phase high-performance liquid chromatography. Although total concentrations of cefonicid in both serum and wound drainage exceeded the MIC for 90% of the isolates of common bacterial pathogens for 24 h, free concentrations in serum and wound drainage (11.0 and 14.9% of total concentrations) were subinhibitory within 6 h following administration. Free concentrations of cefonicid in the postoperative wound drainage were subinhibitory for the entire study period, both perioperatively and postoperatively. Postoperative wound infection occurred significantly (P less than 0.05) more frequently in patients receiving cefonicid (24%) as compared with those receiving clindamycin (8.2%). The relatively low free levels of cefonicid achieved in serum and wound drainage were attributed to the high degree of protein binding (89% in serum) and may be related to the poor clinical outcome. (+info)Randomized, double-blind trial of cefonicid and nafcillin in the treatment of skin and skin structure infections. (5/37)
We compared treatment with one daily intravenous dose of cefonicid and multidose nafcillin in 65 patients with severe infections of the skin or skin structure. Clinical cure or improvement was achieved in 91% of the patients given cefonicid and in 87% of the patients given nafcillin (P = 0.97). The use of cefonicid may allow outpatient therapy of some severe infections. (+info)Perioperative antibiotic prophylaxis for herniorrhaphy and breast surgery. (6/37)
We assessed the efficacy of perioperative antibiotic prophylaxis for surgery in a randomized, double-blind trial of 1218 patients undergoing herniorrhaphy or surgery involving the breast, including excision of a breast mass, mastectomy, reduction mammoplasty, and axillary-node dissection. The prophylactic regimen was a single dose of cefonicid (1 g intravenously) administered approximately half an hour before surgery. The patients were followed up for four to six weeks after surgery. Blinding was maintained until the last patient completed the follow-up and all diagnoses of infection had been made. The patients who received prophylaxis had 48 percent fewer probable or definite infections than those who did not (Mantel-Haenszel risk ratio, 0.52; 95 percent confidence interval, 0.32 to 0.84; P = 0.01). For patients undergoing a procedure involving the breast, infection occurred in 6.6 percent of the cefonicid recipients (20 of 303) and 12.2 percent of the placebo recipients (37 of 303); for those undergoing herniorrhaphy, infection occurred in 2.3 percent of the cefonicid recipients (7 of 301) and 4.2 percent of the placebo recipients (13 of 311). There were comparable reductions in the numbers of definite wound infections (Mantel-Haenszel risk ratio, 0.49), wounds that drained pus (risk ratio, 0.43), Staphylococcus aureus wound isolates (risk ratio, 0.49), and urinary tract infections (risk ratio, 0.40). There were also comparable reductions in the need for postoperative antibiotic therapy, non-routine visits to a physician for problems involving wound healing, incision and drainage procedures, and readmission because of problems with wound healing. We conclude that perioperative antibiotic prophylaxis with cefonicid is useful for herniorrhaphy and certain types of breast surgery. (+info)Effect of age and renal function on cefonicid pharmacokinetics. (7/37)
Cefonicid (15 mg/kg) was administered intravenously at a constant rate of infusion over 15 min to 10 geriatric patients (mean age, 77 years) and to 4 young subjects (mean age, 35 years). Model-dependent and noncompartmental pharmacokinetic parameters were calculated and found to be congruous; noncompartmental data are reported. Significant differences in the values for area under the curve, mean residence time, total body clearance, and renal clearance were observed between the geriatric and young groups. Mean elimination half-life values were 9.59 and 4.88 h for the geriatric and young groups, respectively. Total body and renal clearances were inversely correlated to age and directly correlated to creatinine clearance. Free fraction was not correlated to albumin concentration but was correlated exponentially to total cefonicid concentration. Despite the prolonged half-life values observed in our geriatric patients, the difference in mean trough concentrations was slight. Daily administration of a 15-mg/kg dose should provide adequate concentrations in serum and should not produce appreciable accumulation in geriatric patients. (+info)Evaluation of the bactericidal activity of beta-lactam antibiotics on slowly growing bacteria cultured in the chemostat. (8/37)
The bactericidal activity of 23 beta-lactam antibiotics was compared in slowly growing bacteria cultured in a chemostat. In an attempt to mimic possible in vivo conditions, slowly growing cultures were produced by limitation of iron, glucose, phosphate, or magnesium. Only select antibiotics remained effectively bactericidal against slowly growing cells. For these compounds, the rate of antibiotic-induced loss of viability was a constant when killing was expressed per generation (in contrast to absolute time) in that slowly growing bacteria were killed proportionately more slowly. Individual antibiotics differed greatly, however, in their specific bactericidal activities against slowly growing cells, i.e., in the absolute degree of killing elicited during exposure of the bacteria to MIC equivalents of the drugs. Specific bactericidal activities varied not only with drug structure but also with the bacterial strains and, to a lesser extent, with the nature of the growth-limiting nutrient. In slowly growing cultures exposure to the low drug concentrations studied here (near MIC) caused killing without detectable lysis. Antibiotics with high specific bactericidal activities were capable of rapidly killing cultures of slowly growing pathogens despite extremely long generation times approaching those reported for in vivo growth rates. (+info)
Demi We The Kings Well Be A Dream VID | OCEANUP TEEN GOSSIP
10X PBST Wash Buffer | Grace Bio-Labs
Protein binding on stepped calcite surfaces : simulations of ovocleidin-17 on calcite {31.16} and {31.8} - WRAP: Warwick...
METHOD FOR BLOCKING NON-SPECIFIC PROTEIN BINDING ON A FUNCTIONALIZED SURFACE - Patent application
Plus it
Gambia iTunes Top 20 Songs | Hot Music Charts
After Open-Heart Surgery: In the Hospital
After Open-Heart Surgery: In the Hospital
Houstons Experts In Open-Heart Surgery
Baby smiles for the first time after his second open-heart surgery
Plus it
Surgeon Makes Tutorial DVD For Conscious Open-Heart Surgery - Slashdot
Interview with GCUs Camden Gianni, one year after open-heart surgery
List of 74 Skin and Structure Infection Medications Compared - Drugs.com
Study of skin - Structure of skin |
the dynamic natural skin care
Little Darth Vader Super Bowl Ad Star to Have Open-Heart Surgery - NBC 7 San...
Treatment of uncomplicated skin and skin structure infections in the diabetic patient.<...
Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity...
Effect of Skin Structure Change With Age on Optical Characteristics of Human Skin | AJTEC | ASME Digital Collection
ECG) A 69 year old underwent open-heart surgery 48 hours ago... - Free Medical MCQs
Worlds First Live-Tweeted Open-Heart Surgery is a Success [PICS]
ABSSSI abbreviation stands for Acute Bacterial Skin and Skin Structure Infections
Abstract: Antibiotic Prescribing in Pediatric Patients Hospitalized with Acute Bacterial Skin and Skin Structure Infection ...
Nanoprobes e-News Vol. 4 No. 1 (January 7, 2003)
State Deregulation of Open-heart Surgery -- MEDICA Trade Fair
Haves vs. the `have-nots of open-heart surgery - tribunedigital-baltimoresun
Antibiotics Equal in Skin Infections on NewsHub.org
https://www.medicalnewstoday.com/releases/222684.php
Are We Our Stories? Perhaps We Are… - Diane H. Engelman, Ph.D.
heart disease | Ravishly
Holdings: The village by the sea /
Global Antibiotic Market: Size, Share, Trend and Analysis Report
Cervical Vertebrae | The Chopra Library
DNase I hypersensitivity sites and nuclear protein binding on the fatty acid synthase gene: identification of an element with...
Comparative Study of NXL103 Versus Linezolid in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) - Full...
Prognosis and risk factors in acute, dialysis-requiring renal failure after open-heart surgery
Systemic antibiotics for treating malignant wounds | Cochrane
Dayline 250mg Injection - Chemistree
Cefamandole (Cefamandole Nafate) Panpharma
Alexis Carrel : Quiz (The Full Wiki)
ATC kod J01
J01DC06 Cefonicid. J01DC07 Cefotiam. J01DC08 Lorakarbef. J01DC09 Cefmetazol. J01DC10 Cefprozil. J01DC11 Ceforanid. J01DC12 ...
List of drugs: Cb-Ce
... cefonicid (INN) cefoperazone (INN) ceforanide (INN) cefoselis (INN) Cefotan cefotaxime (INN) cefotetan (INN) cefotiam (INN) ...
Disulfiram-like drug
... cefonicid, cefoperazone, cefotetan, ceftriaxone, and latamoxef (moxalactam); thought to be due to common N-methylthiotetrazole ...
Timeline of antibiotics
... cefonicid 1984 - cefotetan 1984 - temocillin 1985 - cefpiramide 1985 - imipenem/cilastatin, the first carbapenem 1985 - ...
Cefonicid
Cefonicide (or cefonicid) is a cephalosporin antibiotic. It has a density of 1.92g/cm3. Injectable semi-synthetic cephalosporin ... Cefazaflur Saltiel E, Brogden RN (September 1986). "Cefonicid. A review of its antibacterial activity, pharmacological ... antibiotic related to cefamandole, q.v. Cefonicid is synthesized conveniently by nucleophilic displacement of the 3-acetoxy ...
Cefuroxime axetil
InChI=1S/C20H22N4O10S/c1-9(25)33-10(2)34-19(28)15-11(7-32-20(21)29)8-35-18-14(17(27)24(15)18)22-16(26)13(23-30-3)12-5-4-6-31-12/h4-6,10,14,18H,7-8H2,1-3H3,(H2,21,29)(H,22,26)/b23-13-/t10?,14-,18-/m1/ ...
Benzylpenicillin
The production of benzylpenicillin involves fermentation, recovery and purification of the penicillin.[10] The fermentation process of the production of benzylpencillin is about obtaining the product. The presence of the product in solution inhibits the reaction and reduces the product rate and yield. Thus, in order to obtain the most product and increase the rate of reaction the product, would be continuously extracted out.[11] This is done by having the mold with either glucose, sucrose, lactose, startch, or detrin, nitrate, ammonium salt, corn steep liquor, peptone, meat or yeast extract, and little amounts of inorganic salts.[12] The recovery of the benzylpencillin is the most important part of the production process because it affects the purification steps if done wrong.[10] There are many different types of techniques to recover benzyl penicillin, aqueous two-phase extraction, liquid membrane extraction, microfiltration technique, and solvent subulation[10] Extraction is more commonly ...
Meropenem
... , sold under the brandname Merrem among others, is a broad-spectrum antibiotic used to treat a variety of bacterial infections.[1] Some of these include meningitis, intra-abdominal infection, pneumonia, sepsis, and anthrax.[1] It is given by injection into a vein.[1] Common side effects include nausea, diarrhea, constipation, headache, rash, and pain at the site of injection.[1] Serious side effects include Clostridium difficile infection, seizures, and allergic reactions including anaphylaxis.[1] Those who are allergic to other β-lactam antibiotics are more likely to be allergic to meropenem.[1] Use in pregnancy appears to be safe.[1] It is in the carbapenem family of medications.[1] Meropenem usually results in bacterial death through blocking their ability to make a cell wall.[1] It is more resistant to breakdown β-lactamase producing bacteria.[1] Meropenem was patented in 1983.[2] It was approved for medical use in the United States in 1996.[1] It is on the World Health ...
Cefetamet
InChI=1S/C14H15N5O5S2/c1-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24-2)6-4-26-14(15)16-6/h4,8,12H,3H2,1-2H3,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/ ...
Nafcillin
Bonow RO, Carabello BA, Kanu C, et al. (August 2006). "ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons". Circulation. 114 (5): e84-231. doi:10.1161/CIRCULATIONAHA.106.176857. PMID 16880336 ...
Phenoxymethylpenicillin
Penicillin V is sometimes used in the treatment of odontogenic infections.. It is less active than benzylpenicillin (penicillin G) against Gram-negative bacteria.[9][10] Phenoxymethylpenicillin has a range of antimicrobial activity against Gram-positive bacteria that is similar to that of benzylpenicillin and a similar mode of action, but it is substantially less active than benzylpenicillin against Gram-negative bacteria.[9][10]. Phenoxymethylpenicillin is more acid-stable than benzylpenicillin, which allows it to be given orally.. Phenoxymethylpenicillin is usually used only for the treatment of mild to moderate infections, and not for severe or deep-seated infections since absorption can be unpredictable. Except for the treatment or prevention of infection with Streptococcus pyogenes (which is uniformly sensitive to penicillin), therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response.[11] People treated initially with parenteral ...
Ceftolozane
The in vitro activity of ceftolozane-tazobactam has been examined in five surveillance studies of isolates from Europe and North America.[8] In these studies, ceftolozane-tazobactam was notable for its activity against Pseudomonas aeruginosa, a moderately common cause of hospital-acquired infections that is commonly multi-drug resistant. Ninety percent of P. aeruginosa isolates were inhibited by a ceftolozane-tazobactam at a concentration of 4 μg/mL (MIC90), making it the most potent anti-pseudomonal antibiotic in clinical use. In these same studies, ceftolozane-tazobactam exhibited MIC90 values of ,1 μg/mL for Escherichia coli, Citrobacter koseri, Morganella morganii, Proteus mirabilis, Salmonella species, and Serratia marcescens. Somewhat poorer activity is observed for the Klebsiella and Enterobacter species, with the MIC90 for extended spectrum beta-lactamase (ESBL) expressing Klebsiella pneumonia being ,32 μg/mL. ...
Vancomycin
A set of multienzymes (peptide synthase CepA, CepB, and CepC) are responsible for assembling the heptapeptide. (Figure 2). The organization of CepA, CepB, and Cep C closely resembles other peptide synthases such as those for surfactin (SrfA1, SrfA2, and SrfA3) and gramicidin (GrsA and GrsB).[41] Each peptide synthase activates codes for various amino acids to activate each domain. CepA codes for modules 1, 2, and 3. CepB codes for modules 4, 5, and 6, and CepC codes for module 7. The three peptide synthases are located at the start of the region of the bacterial genome linked with antibiotic biosynthesis, and span 27 kb.[41]. After the linear heptapeptide molecule is synthesized, vancomycin has to undergo further modifications, such as oxidative cross-linking and glycosylation, in trans[clarification needed] by distinct enzymes, referred to as tailoring enzymes, to become biologically active (Figure 3). To convert the linear heptapeptide, eight enzymes, open reading frames (ORFs) 7, 8, 9, 10, ...
Cefminox
InChI=1S/C16H21N7O7S3/c1-22-15(19-20-21-22)33-4-7-3-32-14-16(30-2,13(29)23(14)10(7)12(27)28)18-9(24)6-31-5-8(17)11(25)26/h8,14H,3-6,17H2,1-2H3,(H,18,24)(H,25,26)(H,27,28)/t8-,14-,16+/m1/s1 ‹See TfM› ...
Cefdinir
... (SEF-di-nir) is a third-generation oral cephalosporin antibiotic sold under the brand names Cefzon and Omnicef. As of 2008, cefdinir, as Omnicef, was the highest-selling cephalosporin antibiotic in the United States, with more than US$585 million in retail sales of its generic versions alone.[1] Cefdinir is structurally similar to cefixime. It was discovered by Fujisawa Pharmaceutical Co., Ltd. (now Astellas) and introduced in 1991 under the brand name Cefzon.[2][3] Warner-Lambert licensed this cephalosporin for marketing in US from Fujisawa.[4] Abbott obtained U.S. marketing rights to Omnicef (cefdinir) in December 1998 through an agreement with Warner-Lambert Company.[5] It was approved by FDA on Dec 4, 1997.[6] It is available in US as Omnicef by Abbott Laboratories and in India as Cednir by Abbott, Kefnir by Glenmark, Cefdair by Xalra Pharma and Cefdiel by Ranbaxy. ...
Ceftolozane/tazobactam
Ceftolozane exerts bactericidal activities against susceptible gram-negative and gram-positive infections by inhibiting essential penicillin-binding proteins (PBPs), which are required for peptidoglycan cross-linking for bacterial cell wall synthesis, resulting in inhibition of cell wall synthesis and subsequent cell death. Ceftolozane is an inhibitor of PBPs of Pseudomonas aeruginosa (e.g. PBP1b, PBP1c, and PBP3) and E. coli (e.g., PBP3).[6][7] Tazobactam is a potent β-lactamase inhibitor of most common class A and C β-lactamases. Tazobactam has little clinically relevant in vitro activity against bacteria due to its reduced affinity to penicillin-binding proteins; however, it is an irreversible inhibitor of some β-lactamases (certain penicillinases and cephalosporinases) and can covalently bind to some chromosomal and plasmid-mediated bacterial beta-lactamases.[6] The addition of tazobactam strengthens the therapeutic response to ceftolozane, giving it the ability to treat a broader range ...
Cefprozil
... is a second-generation cephalosporin antibiotic. It can be used to treat ear infections, skin infections, and other bacterial infections.[citation needed] It comes as a tablet and as a liquid suspension. Although there is a widely quoted cross-allergy risk of 10% between cephalosporins and penicillin, an article[1] has shown no increased risk for cross-allergy for cefprozil and several other second-generation or later cephalosporins. It was patented in 1983 and approved for medical use in 1992.[2] ...
Imipenem/cilastatin
... has the ability to kill a wide variety of bacteria. Imipenem is the active antibiotic agent and works by interfering with their ability to form cell walls, so the bacteria break up and die. Imipenem is rapidly degraded by the renal enzyme dehydropeptidase if administered alone (making it less effective); the metabolites can cause kidney damage.[11] Imipenem is a broad-spectrum betalactam antibiotic used for severe bacterial infections caused by susceptible organisms. Because imipenem is rapidly inactivated by renal dehydropeptidase I, it is given in combination with cilastatin, a DHP-I inhibitor which increases half-life and tissue penetration of imipenem. Imipenem/cilastatin, like other carbapenems, binds to bacterial penicillin-binding proteins and interferes with bacterial cell wall integrity and synthesis. It has activity against many aerobic and anaerobic Gram-positive and Gram-negative organisms, including Staphylococcus aureus, Streptococcus pyogenes, S. agalactiae, S. ...
Aminoglicozidă
Cefaclor • Cefoxitină • Cefotetan • Cefuroximă (axetil) • Cefamandol‡ • Cefprozil • Cefonicid‡ • Loracarbef‡ (carbacefemă). ...
Stampa:Penicillin
Cefaclor • Cefamandole • Cefminox • Cefonicid • Ceforanide • Cefotiam • Cefprozil • Cefbuperazone • Cefuroxime • Cefuzonam • ...
اسپکتینومایسین - ویکیپدیا
InChI=1S/C14H24N2O7/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14/h5,7-13,15-16,18-20H,4H2,1-3H3/t5-,7-,8+,9+,10+,11-,12-,13+,14+/m1/s1 ...
سفتریاکسون - ویکیپدیا
سفتریاکسون (آیوپاک آدی: (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-,2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, اینگیلیسجه: Ceftriaxone, (چینجه:頭孢曲松)، عربجه: سيفترياكسون، روسجا: Цефтриаксон) بیر شیمیایی بیلشیک دواء. بۇ دواءنین مول جرمیسی مول/قرم ۵۵۴٫۵۸ دیر. نیمه عمر یا یاریلانما سۆرعتی ۵٫۸-۸٫۷ ساعات زامان آپاریر و آنتیبیوتیک اۆچون ایستیفاده اوْلونور. ...
سیکلوسرین - ویکیپدیا
سیکلوسرین (آیوپاک آدی: (R)-4-Amino-1,2-oxazolidin-3-one, اینگیلیسجه: Cycloserine, عربجه: سيكلوسيرين، روسجا: Циклосерин) بیر شیمیایی بیلشیک دواء. بۇ دواءنین مول جرمیسی مول/قرم ۱۰۲٫۰۹۲ دیر. متابولیسمی قاراجییرده باش وئریر. سیکلوسرین آنتیبیوتیک اۆچون ایستیفاده اوْلونور. ...
اسید نالیدیکسیک - ویکیپدیا
اسید نالیدیکسیک (آیوپاک آدی: 1-Ethyl-7-methyl-4-oxo-[1,8]naphthyridine-3-carboxylic acid, اینگیلیسجه: Nalidixic acid, عربجه: حمض الناليديكسيك، روسجا: Налидиксовая кислота) بیر شیمیایی بیلشیک دواء. بۇ دواءنین مول جرمیسی مول/قرم ۲۳۲٫۲۳۵ دیر. متابولیسمی قاراجییرده باش وئریر. اسید نالیدیکسیک آنتیبیوتیک اۆچون ایستیفاده اوْلونور. ...
বিটা ল্যাক্টাম - উইকিপিডিয়া
Cefaclor • Cefamandole • Cefminox • Cefonicid • Ceforanide • Cefotiam • Cefprozil • Cefbuperazone • Cefuroxime • Cefuzonam • ...
سیلور سولفادیازین - ویکیپدیا
سیلور سولفادیازین (آیوپاک آدی: Silver [(4-aminophenyl)sulfonyl](pyrimidin-2-yl)azanide, اینگیلیسجه: Silver sulfadiazine, (چینجه:磺胺嘧啶银)) بیر شیمیایی بیلشیک دواء. بۇ دواءنین مول جرمیسی مول/قرم ۳۵۷٫۱۴ دیر. سیلور سولفادیازین آنتیبیوتیک اۆچون ایستیفاده اوْلونور. ...
استرپتومایسین - ویکیپدیا
InChI=1S/C21H39N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1 ...
Cefonicid - Wikipedia
Cefonicide (or cefonicid) is a cephalosporin antibiotic. It has a density of 1.92g/cm3. Injectable semi-synthetic cephalosporin ... Cefazaflur Saltiel E, Brogden RN (September 1986). "Cefonicid. A review of its antibacterial activity, pharmacological ... antibiotic related to cefamandole, q.v. Cefonicid is synthesized conveniently by nucleophilic displacement of the 3-acetoxy ...
Cefonicid Sodium - New Asiatic Pharm - Drugs.com
A list of US medications equivalent to Cefonicid Sodium - New Asiatic Pharm is available on the Drugs.com website. ... Cefonicid Sodium - New Asiatic Pharm is a medicine available in a number of countries worldwide. ... Cefonicid. Cefonicid sodium (a derivative of Cefonicid) is reported as an ingredient of Cefonicid Sodium - New Asiatic Pharm in ... Cefonicid Sodium - New Asiatic Pharm. Cefonicid Sodium - New Asiatic Pharm may be available in the countries listed below. ...
Cefonicid Injection : Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD
Find patient medical information for Cefonicid Injection on WebMD including its uses, side effects and safety, interactions, ... Does Cefonicid Solution, Reconstituted (Recon Soln) interact with other medications?. Should I avoid certain foods while taking ... More Resources for Cefonicid Solution, Reconstituted (Recon Soln). *Find Lowest Prices on ... How to use Cefonicid Solution, Reconstituted (Recon Soln). Consult your pharmacist or physician. ...
CEFONICID
Sodium Cefonicid | C18H18N6O8S3 - PubChem
Cefonicid sodium | CAS 61270-78-8 | SCBT - Santa Cruz Biotechnology
Buy Cefonicid sodium (CAS 61270-78-8), a broadspectrum cephalosporin antibiotic, from Santa Cruz. Molecular Formula: ... Cefonicid sodium (CAS 61270-78-8) Cefonicid sodium , CAS 61270-78-8 is rated 5.0 out of 5 by 1. ... Rated 5 out of 5 by HF from Cefonicid sodium Cefonicid sodium, reported as a cephalosporin antibiotic whose bactericidal ... Studies indicate that Cefonicid sodium is effective against Escherichia coli, Klebsiella, Citrobacter, Enterobacter, indole- ...
Improved detection of cefonicid with 2D HPLC - Ezine - separationsNOW.com
Standard method for cefonicid HPLC unsuitable for MS It is important to characterise impurities in pharmaceuticals, and often ... Cefonicid that had been subjected to heat treatment gave an additional unknown impurity peak, making seven new impurities in ... Two-dimensional HPLC and MS detect new cefonicid impurities. HPLC was carried out using a Shimadzu two-dimensional Nexera-XR ... The antibiotic cefonicid sodium is commonly used in many countries, typically being administered by injection. The Chinese ...
CAS # 61270-78-8, Cefonicid sodium, Disodium (6R,7R)-7-[[(2R)-2-hydroxy-2-phenyl-acetyl]amino]-8-oxo-3-[[1-(sulfonatomethyl...
Cefonicid | Semantic Scholar
Cefonicid binds to penicillin-binding proteins (PBPs), transpeptidases that are responsible for crosslinking of peptidoglycan. ... Single-dose cefonicid compared with multiple-dose cefamandole.. *S. García, M. Lozano, J. Gatell, E. Soriano, R. Ramón, J. ... Pharmacokinetics of cefonicid, a new broad-spectrum cephalosporin.. *S. Barriere, G. J. Hatheway, J. Gambertoglio, E. Lin, J. ... Cefonicid. Known as: (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-8-oxo-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]sulfanyl} ...
Cefonicid | Johns Hopkins ABX Guide
Cefonicid answers are found in the Johns Hopkins ABX Guide powered by Unbound Medicine. Available for iPhone, iPad, Android, ... Cefonicid is a topic covered in the Johns Hopkins ABX Guide. To view the entire topic, please log in or purchase a subscription ... "Cefonicid." Johns Hopkins ABX Guide, The Johns Hopkins University, 2018. Pediatrics Central, peds.unboundmedicine.com/ ... pedscentral/view/Johns_Hopkins_ABX_Guide/540093/all/Cefonicid. Pham PA, Avdic E. Cefonicid. Johns Hopkins ABX Guide. The Johns ...
Cefonicid | Johns Hopkins ABX Guide
Cefonicid answers are found in the Johns Hopkins ABX Guide powered by Unbound Medicine. Available for iPhone, iPad, Android, ... Cefonicid is a topic covered in the Johns Hopkins ABX Guide. To view the entire topic, please sign in or purchase a ... "Cefonicid." Johns Hopkins ABX Guide, The Johns Hopkins University, 2018. Johns Hopkins Guide, www.hopkinsguides.com/hopkins/ ... view/Johns_Hopkins_ABX_Guide/540093/all/Cefonicid. Pham PA, Avdic E. Cefonicid. Johns Hopkins ABX Guide. The Johns Hopkins ...
August 1991 - Volume 73 - Issue 7 : JBJS
Compound Report Card
ChEMBL Compound Description] ID:, InChI_Key:, Tradenames:MONOCID, Synonyms:SK&F D-75073-Z , MONOCID , CEFONICID SODIUM , ... SK&F D-75073-Z , MONOCID , CEFONICID SODIUM , CEFONICID , SK&F D-75073-Z2 , CEFONICID MONOSODIUM. ... CEFONICID , SK&F D-75073-Z2 , CEFONICID MONOSODIUM ... Cefonicid UniChem Cross References. View the UniChem ...
Cefoperazone Advanced Patient Information - Drugs.com
Cholera Vaccine (Oral Route) Description and Brand Names - Mayo Clinic
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are receiving this vaccine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.. Receiving this vaccine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.. ...
Neuroprotection with Beta-Lactam Compounds - Johns Hopkins University
Category:Penicillin antibiotics - Wikimedia Commons
penicilina (es); Penisillín (is); Penisilin (ms); Penicillin (en-gb); پنسلين (ps); Пеницилин (bg); پنسلین (pnb); پنسلین (ur); Benseliin (so); Penicilín (sk); Penicillina (oc); 青黴素 (zh-hant); Penicilino (io); Penicilline (gsw); 페니실린 (ko); পেনিচিলিন (as); penicilino (eo); пеницилин (mk); Penicilin (bs); Penicilina (an); পেনিসিলিন (bn); pénicilline (fr); Penisilin (jv); Penicilin (hr); پینی سیلین (lrc); פעניצילין (yi); पेनिसिलिन (mr); penicillin (vi); Penicilīni (lv); Penisillien (af); пеницилин (sr); penicilin (cs); Penicilina (pt-br); Penicillin (sco); Пенициллин (mn); penicillin (nn); penicillin (nb); Pénisilin (su); πενικιλίνη (el); Penicillin (fo); ಪೆನ್ಸಿಲಿನ್ (kn); پێنیسیلین (ckb); penicillin (en); بنسلين (ar); Penisilin (br); Пенициллин (kk); ပင်နီဆီလင် (my); 盤尼西林 ...
Compare Current A+Systemic+Inflammatory+Response+Called+Sepsis+Due+To+An+Infection+With+Bacteria Drugs and Medications with...
Molecules | Free Full-Text | Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual Screening...
Monocid - Answers on HealthTap
Patent US8883213 - Ion exchange resin treated to control swelling - Google Patents
... cefonicid, cefotaxime, cefotetan, cefoxitin, ceftriaxone, mezlocillin and piperacillin), antidepressants, (e.g., bupropion, ... cefonicid, cefotaxime, cefotetan, cefoxitin, ceftriaxone, mezlocillin, piperacillin, bupropion, nomifensine, nortriptyline, ... cefonicid, cefotaxime, cefotetan, cefoxitin, ceftriaxone, mezlocillin, piperacillin, bupropion, nomifensine, nortriptyline, ... cefonicid, cefotaxime, cefotetan, cefoxitin, ceftriaxone, mezlocillin, piperacillin, bupropion, nomifensine, nortriptyline, ...
mrcA - Penicillin-binding protein 1A - Escherichia coli (strain K12) - mrcA gene & protein
Abbreviations and Conventions | Journal of Clinical Microbiology
Statistical analysis of data is a crucial component of scientific publication. Authors who are unsure of proper statistical analysis should have their manuscripts checked by a qualified statistician.. The following is a list of important items that must be considered before manuscript submission. Deficiencies in any of these areas may delay review and/or publication.. (i) The same reference (gold) standard should be used for all samples for a given analyte. That reference standard might include more than one test, but it should be used and interpreted consistently for all samples. The reference standard should not include results from the test that is under study.. (ii) Do not use sensitivity or specificity to describe results which compare a new test to a non-reference standard. Use the terms positive percent agreement and negative percent agreement for these results, as recommended by the FDA guidance document Statistical Guidance on Reporting Results from Studies Evaluating ...
ftsI - Peptidoglycan D,D-transpeptidase FtsI precursor - Escherichia coli (strain K12) - ftsI gene & protein
Cranberry Supplementation Does Not Reduce Urinary Tract Infections in Patients With Indwelling Catheters After Pelvic...
Royal Jelly | Memorial Sloan Kettering Cancer Center
Penicillin-binding protein 1A - DrugBank
AGIPS Farmaceutici products
Cefamandole3
- Injectable semi-synthetic cephalosporin antibiotic related to cefamandole, q.v. Cefonicid is synthesized conveniently by nucleophilic displacement of the 3-acetoxy moiety of 1 with the appropriately substituted tetrazole thiole 2. (wikipedia.org)
- Single-dose cefonicid compared with multiple-dose cefamandole. (semanticscholar.org)
- The second generation cephalosporins include: cefaclor (PO), cefamandole (IM/IV), cefonicid (IM/IV), ceforanide (IM/IV) and cefuroxime (PO/IM/IV). (elephantcare.org)
Antibiotic5
- Cefonicide (or cefonicid) is a cephalosporin antibiotic. (wikipedia.org)
- Cefonicid sodium is a broadspectrum cephalosporin antibiotic which inhibits the formation of the bacterial cell wall. (scbt.com)
- Rated 5 out of 5 by HF from Cefonicid sodium Cefonicid sodium, reported as a cephalosporin antibiotic whose bactericidal mechanism of action is cell wall synthesis inhibition. (scbt.com)
- The antibiotic cefonicid sodium is commonly used in many countries, typically being administered by injection. (separationsnow.com)
- Cefonicid is a second-generation cephalosporin-class beta-lactam antibiotic with broad spectrum activity. (mcmaster.ca)
Intravenously or intramuscularly1
- Cefonicid A second-generation cephalosporin administered intravenously or intramuscularly. (sci-toys.com)
Klebsiella1
- Studies indicate that Cefonicid sodium is effective against Escherichia coli, Klebsiella, Citrobacter, Enterobacter, indole-negative Proteus, and Providencia . (scbt.com)
20181
- 2018. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540093/all/Cefonicid. (unboundmedicine.com)
Injection1
- Total serum IgE concentration was 346 kU/L. However, it emerged during the diagnostic procedure that the patient had ingested royal jelly after each injection of cefonicid. (blogspot.com)
Pharmacokinetics2
- Pharmacokinetics of cefonicid, a new broad-spectrum cephalosporin. (semanticscholar.org)
- Effect of saturable serum protein binding on the pharmacokinetics of unbound cefonicid in humans. (asm.org)
Carnitine1
- Studies suggest that Cefonicid sodium can inhibit the carnitine/carnitine antiport when it is added internally and externally to proteoliposomes. (scbt.com)
Ceftriaxone1
- Randomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous bacterial peritonitis in cirrhotic patients. (semanticscholar.org)
Serum1
- Negative results were obtained in immunoassays to determine the presence of immunoglobulin (Ig) E specific to penicilloyl G and V, ampicilloyl, and amoxicilloyl (UniCAP Pharmacia, Uppsala, Sweden) and in a homemade assay of serum specific IgE to cefonicid using epoxy-activated Sepharose as the solid phase [3]. (blogspot.com)
Solution5
- What conditions does Cefonicid Solution, Reconstituted (Recon Soln) treat? (webmd.com)
- List Cefonicid Solution, Reconstituted (Recon Soln) side effects by likelihood and severity. (webmd.com)
- What should I know regarding pregnancy, nursing and administering Cefonicid Solution, Reconstituted (Recon Soln) to children or the elderly? (webmd.com)
- Are you considering switching to Cefonicid Solution, Reconstituted (Recon Soln)? (webmd.com)
- How long have you been taking Cefonicid Solution, Reconstituted (Recon Soln)? (webmd.com)
Data1
- Close examination of the mass spectral output and comparison with the data from cefonicid allowed all seven new impurities to be identified. (separationsnow.com)
Body1
- Cefonicid is throughout body fluids and metabolic acidosis, anticholinergic and sedative drugs.7 the other two subunits are bound in plasma. (equalitymi.org)
Long1
- Cefonicid, a new long-acting cephalosporin, was evaluated for treatment of endocarditis due to Staphylococcus aureus. (semanticscholar.org)